Pancreatitis risk from hypertriglyceridemia typically becomes significant above 500 mg/dL, with acute pancreatitis risk really escalating above 1000 mg/dL. At 358 you were in a gray zone. At 152, that specific risk is negligible.

Regarding statins: with an LDL-C of 108 and a prior ApoB of 158, I'd want to see the updated ApoB before making a definitive call. If your ApoB is still above 90-100 mg/dL, adding a moderate-intensity statin would be reasonable. The lipid-lowering effects of GLP-1 agonists and statins work through different mechanisms (statins upregulate LDL receptor expression; GLP-1 agonists reduce hepatic lipid production), so they're complementary rather than redundant.

Your non-HDL-C of 138 is still above the ideal target of <130 for moderate risk. There's room for further optimization.

This thread is gold. I'm on semaglutide 1.7mg (not at 2.4 yet) and my TGs went from 220 to 165 in 4 months. Not as dramatic as OP but still meaningful. What I really want to know: does tirzepatide have a lipid advantage over semaglutide because of the GIP component? Or is it just about weight loss magnitude?

There's emerging evidence that GIP receptor agonism contributes independently to lipid improvements, particularly for triglycerides. GIP receptors are expressed on adipocytes and play a role in lipid storage and lipoprotein lipase activity.

In the SURPASS-2 trial (tirzepatide vs. semaglutide 1 mg head-to-head), tirzepatide showed greater triglyceride reductions even after adjusting for the difference in weight loss. This suggests a pharmacological advantage beyond just more weight loss.

That said, your 25% TG reduction on semaglutide 1.7 mg is solid. The incremental benefit of switching to tirzepatide for lipids alone probably wouldn't justify it unless there are other reasons (greater weight loss, better glucose control, etc.).

Great clinical discussion. Just a reminder for readers: lipid panels should be drawn fasting (at least 9-12 hours) for accurate triglyceride measurement. If you're seeing dramatically different results, confirm the fasting status was consistent between draws. Non-fasting TGs can be 20-30% higher and lead to misleading comparisons.